Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors

A. Šafanda, M. Kendall Bártů, R. Michálková, M. Švajdler, T. Shatokhina, J. Laco, R. Matěj, G. Méhes, J. Drozenová, J. Hausnerová, Z. Špůrková, J. Škarda, M. Hácová, M. Náležinská, P. Dundr, K. Němejcová

. 2024 ; 19 (1) : 118. [pub] 20240830

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24019230

Grantová podpora
AZV NU21-03-00238 Ministerstvo Zdravotnictví Ceské Republiky

BACKGROUND: Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application. METHODS: We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs. RESULTS: Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases. CONCLUSION: The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019230
003      
CZ-PrNML
005      
20241024111428.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13000-024-01541-x $2 doi
035    __
$a (PubMed)39215355
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Šafanda, Adam $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic
245    14
$a The role of stathmin expression in the differential diagnosis, prognosis, and potential treatment of ovarian sex cord-stromal tumors / $c A. Šafanda, M. Kendall Bártů, R. Michálková, M. Švajdler, T. Shatokhina, J. Laco, R. Matěj, G. Méhes, J. Drozenová, J. Hausnerová, Z. Špůrková, J. Škarda, M. Hácová, M. Náležinská, P. Dundr, K. Němejcová
520    9_
$a BACKGROUND: Stathmin, a cytosolic microtubule-destabilizing phosphoprotein involved in the regulation of mitosis, is widely expressed in various malignancies and acts as an adverse prognostic factor. Our research analyzed its immunohistochemical expression on a large cohort of ovarian sex cord-stromal tumors, evaluating its potential utility in differential diagnosis, prognosis, and therapeutic application. METHODS: We examined 390 cases of ovarian sex cord-stromal tumors including 281 adult granulosa cell tumors (AGCT), 5 juvenile granulosa cell tumors (JGCT), 33 Sertoli-Leydig cell tumors (SLCT), 50 fibromas/thecomas (F/T), 11 Leydig cell tumors/steroid cell tumors (LCT/SterCT), 5 sex-cord stromal tumors NOS (SCST-NOS), 3 Sertoli cell tumors (SCT), and 2 sclerosing stromal tumors (ScST). Immunohistochemical analysis was performed using TMAs. RESULTS: Strong expression (> 50%) was observed in all cases of AGCT, JGCT, SLCT, SCST-NOS, SCT and 1 ScST. The other case of ScST exhibited mild expression (5-10%). The negative cases included exclusively F/T and LCT/SterCT, with F/T showing 24% of negative cases and LCT/SterCT comprising 64% of negative cases. CONCLUSION: The results of our study indicate that stathmin is neither a prognostic marker nor suitable for the differential diagnosis of challenging cases of ovarian sex cord-stromal tumors. However, its predictive value may be theoretically significant, as a decrease in stathmin expression potentialy influences response to chemotherapy treatment.
650    _2
$a lidé $7 D006801
650    12
$a stathmin $x analýza $x metabolismus $7 D050777
650    _2
$a ženské pohlaví $7 D005260
650    12
$a gonadální stromální nádory $x patologie $x diagnóza $x metabolismus $x terapie $7 D018312
650    12
$a nádory vaječníků $x patologie $x diagnóza $x metabolismus $x terapie $7 D010051
650    12
$a nádorové biomarkery $x analýza $7 D014408
650    _2
$a prognóza $7 D011379
650    _2
$a diferenciální diagnóza $7 D003937
650    12
$a imunohistochemie $7 D007150
650    _2
$a dospělí $7 D000328
650    _2
$a lidé středního věku $7 D008875
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kendall Bártů, Michaela $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic
700    1_
$a Michálková, Romana $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic
700    1_
$a Švajdler, Marián $u Šikl's Department of Pathology, The Faculty of Medicine, Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Shatokhina, Tetiana $u Department of Oncological Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Hradec Králové, Czech Republic
700    1_
$a Matěj, Radoslav $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic $u Department of Pathology, Charles University 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, 10034, Czech Republic $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University, Thomayer University Hospital, Prague, Czech Republic
700    1_
$a Méhes, Gábor $u Department of Pathology, Faculty of Medicine, University of Debrecen, Debrecen, 4032, Hungary
700    1_
$a Drozenová, Jana $u Department of Pathology, Charles University 3rd Faculty of Medicine, University Hospital Královské Vinohrady, Prague, 10034, Czech Republic
700    1_
$a Hausnerová, Jitka $u Department of Pathology, University Hospital Brno and Medical Faculty, Masaryk University, Brno, Czech Republic
700    1_
$a Špůrková, Zuzana $u Department of Pathology, Bulovka University Hospital, Prague, Czech Republic
700    1_
$a Škarda, Jozef $u Department of Pathology, University Hospital Ostrava and Faculty of Medicine University of Ostrava, Ostrava, Czech Republic
700    1_
$a Hácová, Mária $u Department of Pathology, The Regional Hospital Pardubice, Pardubice, Czech Republic
700    1_
$a Náležinská, Monika $u Division of Gynecologic Oncology, Department of Surgical Oncology, Masaryk Memorial Cancer Institute and Medical Faculty of Masaryk University, Brno, Czech Republic
700    1_
$a Dundr, Pavel $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic
700    1_
$a Němejcová, Kristýna $u Department of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studničkova 2, Prague 2, 12800, Czech Republic. Kristyna.Nemejcova@vfn.cz $1 https://orcid.org/0000000193409320 $7 xx0233214
773    0_
$w MED00165474 $t Diagnostic pathology $x 1746-1596 $g Roč. 19, č. 1 (2024), s. 118
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39215355 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111422 $b ABA008
999    __
$a ok $b bmc $g 2201841 $s 1231203
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 19 $c 1 $d 118 $e 20240830 $i 1746-1596 $m Diagnostic pathology $n Diagn Pathol $x MED00165474
GRA    __
$a AZV NU21-03-00238 $p Ministerstvo Zdravotnictví Ceské Republiky
LZP    __
$a Pubmed-20241015

Najít záznam

Citační ukazatele

Možnosti archivace